Powered By
Overview
Trastuzumab is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and one or more chemotherapy… read more
Overview
Herceptin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and one or more chemotherapy… read more
Overview
Ado-trastuzumab emtansine is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat some cases of HER2-positive, metastatic breast cancer. Ado-trastuzumab emtansine may be… read more
Overview
Ogivri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer in cases where tumors overexpress the HER2 protein. Ogivri is also known by its drug name,… read more
Overview
Herzuma is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. It is prescribed for people with both early-stage and metastatic (cancer that has spread)…
Trazimera (trastuzumab-qyyp) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with breast cancer.
…
Ontruzant (trastuzumab-dttb) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with breast cancer.
…
Kanjinti (trastuzumab-anns) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with breast cancer.
…
Overview
Kadcyla is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat some cases of HER2-positive, metastatic breast cancer. Kadcyla may be prescribed in cases where trastuzumab and a… read more
Overview
Herceptin Hylecta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjuvant treatment for metastatic breast cancer in cases where tumors overexpress the HER2 protein and one… read more
Join
Your Privacy Choices
